NZ603751A - Composition for treating disease - Google Patents

Composition for treating disease

Info

Publication number
NZ603751A
NZ603751A NZ603751A NZ60375109A NZ603751A NZ 603751 A NZ603751 A NZ 603751A NZ 603751 A NZ603751 A NZ 603751A NZ 60375109 A NZ60375109 A NZ 60375109A NZ 603751 A NZ603751 A NZ 603751A
Authority
NZ
New Zealand
Prior art keywords
domain
chain
seq
composition
sequence identity
Prior art date
Application number
NZ603751A
Inventor
Frank Osterroth
Silke Aigner
Christoph Uherek
Andrea Wartenberg-Demand
Anatoly Rudnev
Michael Soldan
Christoph Bruecher
Benjamin Daelken
Chantal Zuber
Gregor Schulz
Niklas Czeloth
Original Assignee
Biotest Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0817809A external-priority patent/GB0817809D0/en
Priority claimed from GB0817810A external-priority patent/GB0817810D0/en
Priority claimed from GB0817811A external-priority patent/GB0817811D0/en
Priority claimed from PCT/EP2009/052810 external-priority patent/WO2009112502A1/en
Priority claimed from PCT/EP2009/052811 external-priority patent/WO2009124815A1/en
Priority claimed from PCT/EP2009/052809 external-priority patent/WO2009121690A1/en
Application filed by Biotest Ag filed Critical Biotest Ag
Publication of NZ603751A publication Critical patent/NZ603751A/en

Links

Abstract

603751 Disclosed is a kit comprising separately a humanized anti-CD4 antibody capable of activating CD4+CD25+ regulatory T cells and methotrexate, wherein the humanized anti-CD4 antibody comprises an H chain V domain, an L chain V domain and an IgG 1 constant domain, and wherein: (a) the H chain V domain compnses the sequences DCRMY, VISVKSENYGANYAESVRG and SYYRYDVGAWFAY, and the L chain V domain comprises the sequences RASKSVSTSGYSYIY, LASILES and QHSRELPWT; and/or (b) the H chain V domain has at least 80% sequence identity with SEQ ID No: 1 and the L chain V domain has at least 80% sequence identity with SEQ ID No: 2. Further disclosed is the therapeutic use of said combinations for treating rheumatic diseases such as rheumatoid arthritis.
NZ603751A 2008-09-29 2009-08-31 Composition for treating disease NZ603751A (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB0817809A GB0817809D0 (en) 2008-09-29 2008-09-29 Agent for treating disease
GB0817810A GB0817810D0 (en) 2008-09-29 2008-09-29 Agent for treating disease
GB0817811A GB0817811D0 (en) 2008-09-29 2008-09-29 Agent for treating disease
PCT/EP2009/052810 WO2009112502A1 (en) 2008-03-13 2009-03-10 Agent for treating disease
PCT/EP2009/052811 WO2009124815A1 (en) 2008-03-13 2009-03-10 Agent for treating disease
PCT/EP2009/052809 WO2009121690A1 (en) 2008-03-13 2009-03-10 Agent for treating disease
NZ59210209 2009-08-31

Publications (1)

Publication Number Publication Date
NZ603751A true NZ603751A (en) 2014-04-30

Family

ID=50624334

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ603751A NZ603751A (en) 2008-09-29 2009-08-31 Composition for treating disease

Country Status (1)

Country Link
NZ (1) NZ603751A (en)

Similar Documents

Publication Publication Date Title
NZ598063A (en) Gram-positive bacteria specific binding compounds
MX2020001873A (en) Binding agents.
PH12015501763A1 (en) Humanized anti-factor d antibodies and uses thereof
NZ623319A (en) Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
NZ602892A (en) Antibodies that bind human cd27 and uses thereof
NZ588457A (en) Humanized anti-factor d antibodies and uses thereof
MX2010006181A (en) Anti-human il-21 monoclonal antibodies.
WO2010017103A3 (en) Fully human anti-human nkg2d monoclonal antibodies
NZ597466A (en) Recombinant anti-epidermal growth factor receptor antibody compositions
NZ610734A (en) Human antibodies to the glucagon receptor
NZ594682A (en) Fully human antibodies specific to cadm1
NZ599140A (en) Antibodies that specifically bind to the epha2 receptor
PH12017501075B1 (en) Human monoclonal antibody with specificity for dengue virus serotype 1 e protein and uses thereof
NZ584838A (en) Novel antibodies which bind alpha5beta1 (fibronectin receptor) and uses thereof
MX2009005743A (en) NEW Abeta CONFORMER SELECTIVE ANTI-Abeta GLOBULOMER MONOCLONAL ANTIBODIES.
NZ595792A (en) Antibodies specific to cadherin-17
NZ592214A (en) Improved Interleukin-6 receptor antibody molecule
MX2012000316A (en) Humanised antibodies to toll-like receptor 2 and uses thereof.
NZ714516A (en) Human antibodies to clostridium difficile toxins
SG155186A1 (en) Il-17 antagonistic antibodies
EA200702180A1 (en) METHODS FOR THE TREATMENT OF IMMUNE DISORDERS RELATED TO TRANSPLANT TRANSPLANT WITH SOLUBLE MUTANT CTLA4
NZ600768A (en) Human antibodies to human angiopoietin-like protein 4
MX2011008971A (en) ANTI-CεmX ANTIBODIES CAPABLE OF BINDING TO HUMAN mIgE ON B LYMPHOCYTES.
NZ601271A (en) Cd127 binding proteins
PE20090161A1 (en) MONOCLONAL ANTIBODIES ANTI CXCL13

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 31 AUG 2016 BY CPA GLOBAL

Effective date: 20140926

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 AUG 2017 BY CPA GLOBAL

Effective date: 20160715

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 AUG 2018 BY CPA GLOBAL

Effective date: 20170720

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 AUG 2019 BY CPA GLOBAL

Effective date: 20180719

LAPS Patent lapsed